Berkshire’s Cash Bulk… And New Data In The Weight Loss Drug Race 11/4/24

Bitcoin feeling the Thanksgiving hangover as the crypto space sells off. The tokens leading the losses, and how the Bitcoin treasury companies are feeling the pain as well. Plus Why the AI tech rally can keep rocking in the new year. Where one top tech analyst sees the most opportunity, as investors digest the latest AI power partnership.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Around the country, a pervasive question being asked: How can I afford my prescription drugs? The high cost of those medications, particularly very expensive drugs to treat serious diseases like multiple sclerosis and cystic fibrosis, have fueled a nationwide business in which insurance programs are using companies called “alternative funding programs” or AFPs that promise to get these medications at little or no cost to the patient. “RiskyRX,” a CNBC investigation, found AFPs are becoming more pervasive around the country as drug costs skyrocket.CNBC submitted nearly 100 public records requests and sorted through more than 10,000 pages of contracts, emails, invoices and complaints that show these companies have penetrated the country’s health-care system through private employers, cities, counties, school districts and unions. In some cases, employers require their staff to use an AFP. CNBC traced the trail of medications from abroad to the U.S. via a supply chain that’s not authorized by the pharmaceutical companies that manufacture the medications. The investigation features an exclusive interview with a Department Of Homeland Security official who says these programs should be shut down because they’re illegal and post a serious safety risk to patients. A former high-ranking FDA official, speaking out for the first time, says these programs typically don’t disclose the risks to patients. The AFPs strongly defend their business practices as both legal and safe and say their businesses are an antidote to high prescription drug prices. Those prices, across all drugs, in the U.S. are nearly three times as much, on average, as those in other high-income countries, according to a 2024 report by Rand, a nonprofit, nonpartisan research organization. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Stocks closing out the week with a big leg higher, as equities rebound after an Nvidia led sell-off on Thursday. The sectors gaining ground, and if the volatility will continue into a shortened holiday week. Plus Rounding up all the retail data and results that came in this week, the huge move in airlines, restaurants, and housing stocks, and where to find opportunity in the credit markets.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

An early rally in stocks gave way to a rough sell-off on Wall Street. How Nvidia’s reversal, and a delayed jobs report gave way to a market meltdown, and how Walmart became a bright spot in the down day. Plus, Biotech more than doubling the performance of the broader market, as M&A action lights up the space. Where our next guest sees the most opportunity in the space, and if the biotech boom can continue into year end.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nvidia on the move after reporting results. The numbers and details from their latest quarter, and what a top semi analyst sees in store for the chip giant. Plus Shoppers skipping the trips to Target. The disappointing numbers out of the retailers results, and the implications it could have ahead of the holiday season.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Amazon and Microsoft getting hit on lingering concerns over AI’s sky-high valuation. What analysts are flagging about the buildout, and what it all means ahead of Nvidia’s earnings report tomorrow. Plus Why one analyst says the weakness in health care stocks is a major buying opportunity, the sports betting drama between Draftkings, Fanduel, and the American Gaming Association, and the next move for nuclear stocks after a rough month for the group.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Shares of Nvidia down nearly 10% in November as the semi giant gears up to report results on Wednesday. How our traders are positioning ahead of that report, and what Jim Cramer sees in store for the AI darling heading into year end. Plus Could Tesla be about to charge higher? Shares nearly flat on the year, but one wall street firm is plugging into the EV maker for its next leg higher. What they say could power the move, and just how high this stock can go.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.